Acutaas Chemicals Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/lo5p7d64skk2s2d5iwq4tp3c.pdf

Key Takeaways


Revenue Growth & Segment Performance

Naresh Patel: "Together, these 2 verticals, battery chemicals and semiconductors will serve as important growth pillar for us alongside our CDMO business, where we are witnessing a healthy increase in customer enquiries and new molecule additions to our CDMO pipeline."

Margin Structure & Sustainability

Abhishek Patel: "We have slowly started redefining our product portfolio in such a way that we churn out some of the low-margin products and focus on something, which is more sustainable and with a sustainable revenue growth."

CDMO Business & Pipeline

Abhishek Patel: "We now are EcoVadis Platinum certified company, which is only 1% of the companies over the world are into this territory. So this gives us the confidence that because of this, we are able to sustain -- in fact, get a good share of this business in the market."

New Verticals: Battery, Semiconductor & Korea


Competitive Position & Strategy

Naresh Patel: "We are a very strong chemistry-driven company. So basically, chemistry don't have an application only in pharma. So we want to expand our chemistry base out of pharma, and that's why we started acquiring Gujarat Organics and then we entered into the battery and then later on, we acquired Baba and now we enter into the semicon."

Capex, Capacity & Balance Sheet


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthAround 25% for FY26FY26 full year
EBITDA margin28–30% range (raised from prior guidance)FY26 full year
Electrolyte additive productionCommence at Jaghadia plantQ4 FY26
CDMO new product revenueStart contributing, subject to regulatory approvalEnd of FY26
Indichem Korea JV revenueCommercial revenue beginsH2 FY27
Block 3 CDMO capacity utilizationReach optimum levelWithin 2 years
Electrolyte additive capacity rampReach optimum utilization~3 years from start
Working capital days95–105 daysFY26 full year
Traditional spec-chem growth10–15% growth territoryBy end of FY26

Key Metrics

MetricQ2 FY26
Revenue from operations₹306.2 cr, +24.1% YoY
H1 FY26 revenue₹513.4 cr, +21.3% YoY
Gross profit₹170.7 cr, +59.3% YoY
Gross margin55.8%, expanded 1,232 bps YoY
EBITDA₹95.3 cr, grew almost 2x YoY
EBITDA margin31.1%, up 1,130 bps YoY
PAT₹71.9 cr, +91.3% YoY
PAT margin23.5%, expanded 824 bps YoY
FY26 revenue growth guidance~25%
FY26 EBITDA margin guidance28% to 30%, revised upward
Pharma Intermediates segment revenue₹262.6 cr, +27.1% YoY
Specialty Chemicals segment revenue₹43.6 cr, +7.3% YoY
Net cash and cash equivalents₹240.6 cr as of Sep 30, 2025
Working capital days100 days, improved 28 days QoQ
H1 FY26 capex₹141 cr, full-year plan ~₹250 cr
Trade receivables days87 days
Specialty Chemicals capacity utilization (Jaghadia)52%
CDMO Block 3 capacity utilization (Unit 2)38%